The oncolytic activity of newcastle disease virus in clear cell renal carcinoma cells in normoxic and hypoxic conditions: The interplay between von hippel-lindau and interferon-β signaling

Journal of Interferon and Cytokine Research

Volumn 33, Issue 7, 2013, Pages 346-354

  Ch'Ng, Wei Choong ^a   Stanbridge, Eric J ^b   Yusoff, Khatijah ^a   Shafee, Norazizah ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AF 2240; ALPHA INTERFERON; BETA INTERFERON; HYPOXIA INDUCIBLE FACTOR 2ALPHA; ONCOLYTIC NEWCASTLE DISEASE PARAMYXOVIRUS; ONCOLYTIC PARAMYXOVIRUS; STAT1 PROTEIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; AVULAVIRUS INFECTION; CELL DEATH; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; HYPOXIA; KIDNEY CARCINOMA; NEWCASTLE DISEASE PARAMYXOVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; ANOXIA; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-BETA; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIROTHERAPY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; TRANSGENES; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 84880244328     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2012.0095     Document Type: Article

References (52)

1. Aaronson DS, Horvath CM. 2002. A road map for those who don't know JAK-STAT. Science 296(5573):1653-1655. (Pubitemid 34579157)
2. Ahmad A, Ahmad S, Glover L, Miller SM, Shannon JM, Guo X, Franklin WA, Bridges JP, Schaack JB, Colgan SP, White CW. 2009. Adenosine A2A receptor is a unique angiogenic target of HIF-2alpha in pulmonary endothelial cells. Proc Natl Acad Sci USA 106(26):10684-10689.
3. Alabsi AM, Bakar SA, Ali R, Omar AR, Bejo MH, Ideris A, Ali AM. 2011. Effects of Newcastle disease virus strains AF2240 and V4-UPM on cytolysis and apoptosis of leukemia cell lines. Int J Mol Sci 12(12):8645-8660.
4. Alexander DJ. 1988. Newcastle disease virus-An avian paramyxovirus. In: Alexander DJ, ed. Newcastle disease. Boston: Kluwer Academic. pp 11-22.
5. Ali R, Alabsi AM, Ali AM, Ideris A, Omar AR, Yusoff K, Saif-Ali R. 2011. Cytolytic effects and apoptosis induction of Newcastle disease virus strain AF2240 on anaplastic astrocytoma brain tumor cell line. Neurochem Res 36(11):2051-2062.
6. Cassel WA, Garrett RE. 1965. Newcastle disease virus as an antineoplastic agent. Cancer 18:863-868.
7. Chawla-Sarkar M, Leaman DW, Borden EC. 2001. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: Correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res 7(6):1821-1831. (Pubitemid 32708654)
8. Collins JA, Schandi CA, Young KK, Vesely J, Willingham MC. 1997. Major DNA fragmentation is a late event in apoptosis. J Histochem Cytochem 45(7):923-934. (Pubitemid 27284016)
9. Colonne PM, Eremeeva ME, Sahni SK. 2011. Beta interferonmediated activation of signal transducer and activator of transcription protein 1 interferes with Rickettsia conorii replication in human endothelial cells. Infect Immun 79(9): 3733-3743.
10. Connor JH, Naczki C, Koumenis C, Lyles DS. 2004. Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo. J Virol 78(17):8960-8970. (Pubitemid 39096508)
11. Cooray S, Best JM, Jin L. 2003. Time-course induction of apoptosis by wild-type and attenuated strains of rubella virus. J Gen Virol 84(Pt 5):1275-1279. (Pubitemid 36592621)
12. Cowey CL, Hutson TE. 2010. Molecularly targeted agents for renal cell carcinoma: The next generation. Clin Adv Hematol Oncol 8(5):357-364.
13. Dranoff G. 2004. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4(1):11-22. (Pubitemid 38111131)
14. Elankumaran S, Chavan V, Qiao D, Shobana R, Moorkanat G, Biswas M, Samal SK. 2010. Type I interferon-sensitive recombinant Newcastle disease virus for oncolytic virotherapy. J Virol 84(8):3835-3844.
15. Fiola C, Peeters B, Fournier P, Arnold A, Bucur M, Schirrmacher V. 2006. Tumor selective replication of Newcastle disease virus: Association with defects of tumor cells in antiviral defence. Int J Cancer 119(2):328-338.
16. Flint SJ, Enquist LW, Racaniello VR, Skalka AM. 2008. Principles of virology. Washington, DC: ASM Press. pp 592.
17. Hwang IIL, Watson IR, Der SD, Ohh M. 2006. Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: Role of HIF in antiviral response. J Virol 80(21):10712-10723. (Pubitemid 44628917)
18. Ihle JN, Witthuhn BA, Quelle FW, Yamamoto K, Thierfelder WE, Kreider B, Silvennoinen O. 1994. Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci 19(5):222-227. (Pubitemid 24187246)
19. Iliopoulos O, Kibel A, Gray S, Kaelin WG, Jr. 1995. Tumour suppression by the human von Hippel-Lindau gene product. Nat Med 1(8):822-826.
20. Ivanov SV, Salnikow K, Ivanova AV, Bai L, Lerman MI. 2007. Hypoxic repression of STAT1 and its downstream genes by a pVHL/HIF-1 target DEC1/STRA13. Oncogene 26(6):802-812.
21. Jamal MH, Ch'ng WC, Yusoff K, Shafee N. 2012. Reduced Newcastle disease virus-induced oncolysis in a subpopulation of cisplatin-resistant MCF7 cells is associated with survivin stabilization. Cancer Cell Int 12(1):35.
22. Kaelin WG, Jr. 2008. The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8(11):865-873.
23. Keith B, Johnson RS, Simon MC. 2012. HIF1alpha and HIF2alpha: Sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12(1):9-22.
24. Kile BT, Alexander WS. 2001. The suppressors of cytokine signalling (SOCS). Cell Mol Life Sci 58(11):1627-1635. (Pubitemid 32996098)
25. Koul H, Huh JS, Rove KO, Crompton L, Koul S, Meacham RB, Kim FJ. 2011. Molecular aspects of renal cell carcinoma: A review. Am J Cancer Res 1(2):240-254.
26. Krishnamurthy S, Takimoto T, Scroggs RA, Portner A. 2006. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 80(11):5145-5155.
27. Lofstedt T, Fredlund E, Holmquist-Mengelbier L, Pietras A, Ovenberger M, Poellinger L, Pahlman S. 2007. Hypoxia inducible factor-2alpha in cancer. Cell Cycle 6(8):919-926.
28. Lopez-Beltran A, Carrasco JC, Cheng L, Scarpelli M, Kirkali Z, Montironi R. 2009. 2009 update on the classification of renal epithelial tumors in adults. Int J Urol 16(5):432-443.
29. Lu X, Kang Y. 2010. Hypoxia and hypoxia-inducible factors: Master regulators of metastasis. Clin Cancer Res 16(24):5928-5935.
30. Maclachlan NJ, Edward JD. 2011. Chapter 17: Paramyxoviridae. In: Fenner's veterinary virology, 4th ed. San Diego: Academic Press. pp 299-325.
31. Mansour M, Palese P, Zamarin D. 2011. Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J Virol 85(12):6015-6023.
32. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ. 1999. The tumour suppressor protein VHL targets hypoxiainducible factors for oxygen-dependent proteolysis. Nature 399(6733):271-275. (Pubitemid 29246458)
33. Pensa S, Regis G, Boselli D, Novelli F, Poli V. 2009. STAT1 and STAT3 in tumorigenesis. In: Stephanou A, ed. JAK-STAT pathway in disease. Texas: Landes Bioscience Books. pp 100-121.
34. Rawlings JS, Rosler KM, Harrison DA. 2004. The JAK/STAT signaling pathway. J Cell Sci 117(Pt 8):1281-1283. (Pubitemid 38559804)
35. Reichard KW, Lorence RM, Cascino CJ, Peeples ME, Walter RJ, Fernando MB, Reyes HM, Greager JA. 1992. Newcastle disease virus selectively kills human tumor cells. J Surg Res 52(5):448-453.
36. Reu FJ, Bae SI, Cherkassky L, Leaman DW, Lindner D, Beaulieu N, MacLeod AR, Borden EC. 2006. Overcoming resistance to in-terferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol 24(23):3771-3779. (Pubitemid 46622316)
37. Roos FC, Roberts AM, Hwang IIL, Moriyama EH, Evans AJ, Sybingco S, Watson IR, Carneiro LA, Gedye C, Girardin SE, Ailles LE, Jewett MA, Milosevic M, Wilson BC, Bell JC, Der SD, Ohh M. 2010. Oncolytic targeting of renal cell carcinoma via encephalomyocarditis virus. EMBO Mol Med 2(7):275-288.
38. Sanceau J, Hiscott J, Delattre O, Wietzerbin J. 2000. IFN-beta induces serine phosphorylation of Stat-1 in Ewing's sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Oncogene 19(30):3372-3383. (Pubitemid 30479332)
39. Schirrmacher V, Fournier P. 2009. Newcastle disease virus: A promising vector for viral therapy, immune therapy, and gene therapy of cancer. Methods Mol Biol 542:565-605.
40. Semenza GL. 2012. Hypoxia-inducible factors in physiology and medicine. Cell 148(3):399-408.
41. Sinkovics JG, Horvath JC. 2000. Newcastle disease virus (NDV): Brief history of its oncolytic strains. J Clin Virol 16(1):1-15. (Pubitemid 30066477)
42. Song MM, Shuai K. 1998. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem 273(52):35056-35062. (Pubitemid 29028206)
43. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N, Bell JC. 2000. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6(7):821-825. (Pubitemid 30469434)
44. Strauss WM. 1998. Preparation of genomic DNA from mammalian tissue. In: Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K, eds. Current protocols in molecular biology. New York: John Wiley & Sons, Inc. pp 2.2.1-2.2.3.
45. Toshchakov V, Jones BW, Perera P-Y, Thomas K, Cody MJ, Zhang S, Williams BRG, Major J, Hamilton TA, Fenton MJ, Vogel SN. 2002. TLR4, but not TLR2, mediates IFN-[beta]-induced STAT1[alpha]/[beta]-dependent gene expression in macrophages. Nat Immunol 3(4):392-398. (Pubitemid 34308628)
46. Toth CA, Thomas P. 1992. Type I interferon resistance in a colorectal cancer cell line is associated with a more aggressive phenotype in vivo. Br J Cancer 65(3):365-368.
47. Wiesener MS, Turley H, Allen WE, Willam C, Eckardt KU, Talks KL, Wood SM, Gatter KC, Harris AL, Pugh CW, Ratcliffe PJ, Maxwell PH. 1998. Induction of endothelial PAS domain protein-1 by hypoxia: Characterization and comparison with hypoxia-inducible factor-1alpha. Blood 92(7):2260-2268. (Pubitemid 28452966)
48. Wong HH, Lemoine NR, Wang Y. 2010. Oncolytic viruses for cancer therapy: Overcoming the obstacles. Viruses 2(1):78-106.
49. Yusoff K, Tan WS. 2001. Newcastle disease virus: Macromolecules and opportunities. Avian Pathol 30(5):439-455. (Pubitemid 32931159)
50. Yusoff K, Tan WS, Lau CH, Ng BK, Ibrahim AL. 1996. Sequence of the haemagglutinin-neuraminidase gene of the Newcastle disease virus oral vaccine strain V4(UPM). Avian Pathol 25(4): 837-844. (Pubitemid 27052451)
51. Zitzmann K, Brand S, De Toni EN, Baehs S, Goke B, Meinecke J, Spottl G, Meyer HH, Auernhammer CJ. 2007. SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res 67(10): 5025-5032. (Pubitemid 46910213)
52. Zorn U, Dallmann I, Grosse J, Kirchner H, Poliwoda H, Atzpodien J. 1994. Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother 9(3):225-235. Innovation